Related Experiment Video
Updated: Jun 16, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Paroxysmal cortical slowing linked to drug-resistant epilepsy
Yonatan Serlin1, Hamza Imtiaz2, Tamir Avigdor3
1Neurophysiology of Epilepsy Unit, NINDS, National Institutes of Health, Bethesda, MD, USA; Department of Medical Neuroscience and the Brain Repair Center, Dalhousie University, Faculty of Medicine, Halifax, NS, Canada.
Background:
Paroxysmal slow wave events (PSWEs), defined as electroencephalography (EEG) segments where the median power frequency falls below 6 Hz for ≥5 s, have been shown to predict epilepsy in patients with a first seizure. We evaluated the prevalence and localisation of PSWEs in large independent EEG datasets, exploring their potential as biomarkers for drug-resistant epilepsy (DRE).
Methods:
An exploratory analysis used 1064 participants from the Temple University EEG corpus, comparing patients with epilepsy (N = 903) with participants with seizure-mimics and normal EEGs (N = 161). Validation analysis used an independent cohort from Bonn University, comprising drug-responsive (N = 51) and patients with DRE (N = 44).
Findings:
In the exploratory analysis, the proportion of time PSWEs were detected was longer in epilepsy compared with participants without epilepsy (P < 0.0001). Analyses of aetiology and EEG localisation revealed that PSWEs were most prolonged in patients with reported focal epilepsy (P = 0.004), particularly with temporal lobe involvement (P = 0.005). Patients with DRE had prolonged time in PSWEs (P = 0.005), corresponding with an increased risk of refractoriness (OR = 1.9; 95% CI 1.2-2.9). Validation analysis confirmed these findings, with prolonged PSWEs in DRE vs. drug-responsive patients (P < 0.0001, AUC = 0.829). Based on the cutoff established in the exploratory cohort, prolonged time in PSWEs in the validation cohort was associated with increased DRE risk (OR = 5.14, 95% CI 2.1-12.3). In patients with poor surgical outcomes (Engel IB-IV, N = 13), pre-surgical EEGs showed prolonged time in PSWEs compared with Engel IA (N = 24, P = 0.038).
Interpretation:
Analysis of 1159 EEGs from two independent cohorts demonstrated that PSWEs are more prevalent and prolonged in patients with focal epilepsy and may indicate a lack of therapeutic response.
Funding:
The Canadian Institutes of Health Research (168164, 180636).
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

